SCHEMBL4015666

SCHEMBL4015666

O=C(O)C1Cc2ccc(F)cc2C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
NOTUM Q6P988 2/20 0.40
HTT P42858 1/20 0.40
ACHE P22303 1/20 0.40
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
SLC6A4 P31645 1/20 0.39
NOS3 P29474 2/20 0.38
NOS2 P35228 1/20 0.38
DPP4 P27487 2/20 0.37
DPP8 Q6V1X1 2/20 0.37
DPP9 Q86TI2 2/20 0.37
TSHR P16473 1/20 0.36
DPP7 Q9UHL4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24440190 0.86 HDAC8 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL31262473 0.86 HDAC8 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL17443352 0.86 HTR1D (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL11357800 0.83 LTA4H (0.42) NOTUMHTTTSHR
SCHEMBL935855 0.83 NOTUM (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL31293455 0.81 MAOB (0.46) HTTACHENOS3NOS2
SCHEMBL7245995 0.81 MAOB (0.46) HTTACHENOS3NOS2
SCHEMBL27725838 0.80 NOTUM (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL29456780 0.79 TSHR (0.44) NOTUMHTTTSHR
SCHEMBL13419450 0.79 TSHR (0.44) NOTUMHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049060-A1 TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS NATIONAL HEALTH RES INST (TW) 2026-02-19 US disclosed
US-10927092-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARM INC (US) 2021-02-23 US disclosed
US-20190263775-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARM INC (US) 2019-08-29 US disclosed
US-10227323-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMACEUTICAL INC. (US) 2019-03-12 US disclosed
US-20160229830-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2016-08-11 US disclosed
US-20160229830-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2016-08-11 US disclosed
WO-2015042397-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. (US) 2015-03-26 WO disclosed
US-7598417-B2 Analgesics; muscular disorders; diarrhea ALLERGAN, INC. (US) 2009-10-06 US disclosed
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ALLERGAN, INC. 2008-10-16 US disclosed
CN-1332952-C 4-substituted imidazole-2-thiones, 4-substituted imidazole-2-ones and related compounds and their use ALLERGAN INC (US) 2007-08-22 CN disclosed
CN-1671671-A 4- (substituted cycloalkylmethyl) imidazole-2-thiones, 4- (substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones, and 4- (substituted cycloalkenylmethyl) imidazol-2-ones, and related compounds ALLERGAN INC (US) 2005-09-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049060-A1 TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS OPRK1, OPRD1, OPRM1 PSEN1 4704/4885PSEN2 4701/4885APH1B 4545/4885
US-10927092-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 PSEN1 876/4885PSEN2 1032/4885APH1B 981/4885
US-20160229830-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 PSEN1 876/4885PSEN2 1032/4885APH1B 981/4885
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ADRB2, ADRA2A, ADRA2C PSEN1 4237/4885PSEN2 3029/4885APH1B 3794/4885
US-10227323-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 PSEN1 876/4885PSEN2 1032/4885APH1B 981/4885
US-20190263775-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 PSEN1 876/4885PSEN2 1032/4885APH1B 981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.